Skip main navigation

Military Health System

Clear Your Browser Cache

This website has recently undergone changes. Users finding unexpected concerns may care to clear their browser's cache to ensure a seamless experience.

2023-2024 Mid-Season Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Hospitalizations: U.S. Active Component Service Members

Image of 48088663. This report provides data supporting use of influenza vaccines among typically healthy service members to prevent influenza hospitalization.

This Surveillance Snapshot provides an overview of the 2023-2024 mid-season analysis of influenza VE against influenza hospitalizations among ACSMs. Data from the DMSS and standardized laboratory data provided by DCPH–Portsmouth were utilized for this analysis.1 A cohort study design was implemented among the population of ACSMs in service at any time between September 1, 2023 and February 14, 2024. 

The outcome was defined as a laboratory-confirmed influenza-positive result (rapid antigen, RT-PCR, or culture influenza assay) with an indication that the individual was hospitalized, or a hospitalization record with the first or second diagnostic International Classification of Diseases, 10th revision code for influenza (J09-J11). Person-time started at the beginning of the surveillance period or entry into active component service (whichever came last) and was censored at either the occurrence of the outcome, end of the surveillance period, or leaving active component or military service (whichever came first). Person-time and outcomes were stratified by vaccination status. Person-time and outcomes occurring prior to vaccination and up to 13 days post-vaccination were defined as unvaccinated. Person-time and outcomes occurring at least 14 days after vaccination were defined as vaccinated. Analyses were conducted for laboratory-confirmed influenza hospitalizations alone and then combined with hospitalization records for influenza. Incidence rates per 100,000 person-years (p-yrs) were calculated and a Poisson regression model was used to calculate adjusted incidence rate ratios (adjusted for sex, age category, prior vaccination [any influenza vaccine within previous five years], and month of diagnosis) and 95% CIs. VE was defined as (1 - OR) x 100. 

There were 47 laboratory-confirmed influenza hospitalizations among ACSMs during the study period. An additional 17 influenza hospitalization records were identified using the encounter data. For both outcomes, the incidence rate of influenza hospitalization among unvaccinated ACSMs was twice the rate of vaccinated ACSMs (lab-confirmed only: 1.0 vs. 0.5 per 100,000 p-yrs; lab-confirmed and hospitalization records: 1.4 vs. 0.7 per 100,000 p-yrs) (Table). Likewise, the adjusted analysis resulted in VE estimates of 46% (95% CI: 2, 70) and 54% (95% CI: 12, 72) for the laboratory-confirmed only and laboratory-confirmed with hospitalization records, respectively. 

Click on the table to access a 508-compliant PDF version

The results of this analysis show moderate protection against hospitalization for influenza among ACSMs from the 2023-2024 seasonal influenza vaccines. Although the number of outcomes are small, the analysis still reached statistical significance and provides data supporting the use of influenza vaccines among typically healthy ACSMs to prevent influenza hospitalizations. 

Reference

  1. Rubertone MV, Brundage JF. The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance. Am J Public Health. 2002;92(12):1900-1904. doi:10.2105/ajph.92.12.1900

You also may be interested in...

Article
Mar 1, 2024

Coverage of HIV Pre-Exposure Prophylaxis Within the Active Duty U.S. Military, 2023

This study provides the first estimate of HIV pre-exposure prophylaxis coverage in the U.S. military, defined as the proportion of the persons taking HIV PrEP out of the estimated number of persons who had indications for it, that is also comparable to U.S. civilian estimates. The population with indications for HIV PrEP was obtained from the ...

Article
Mar 1, 2024

Mid-Season Influenza Vaccine Effectiveness Estimates Among DOD Populations: A Composite of Data Presented at VRBPAC—the Vaccines and Related Biological Products Advisory Committee—2024 Meeting on Influenza Vaccine Strain Selection for the 2024-2025 Influenza Season

This is an introduction to a composite of three Surveillance Snapshots of Department of Defense data on mid-season influenza vaccine effectiveness that were presented at the 2024 VRBPAC meeting.

Article
Mar 1, 2024

Tobacco and Nicotine Use Among Active Component U.S. Military Service Members: A Comparison of 2018 Estimates from the Health Related Behaviors Survey and the Periodic Health Assessment

This study compared estimates of the prevalence of and risk factors for tobacco and nicotine use obtained from the 2018 Health Related Behaviors Survey and Periodic Health Assessment survey. The HRBS and the PHA are important Department of Defense sources of data on health behavior collected from U.S. military service members.

Report
Mar 1, 2024

MSMR Vol. 31 No. 3 - March 2024

.PDF | 1.34 MB

The March 2024 MSMR features a comparison of 2018 estimates from the HRBS and the PHA on tobacco and nicotine use among the U.S. military active component; followed by a report on coverage of HIV PrEP among active duty service members in 2023; supplemented by a Surveillance Snapshot of HIV PrEP prescriptions in 2023 in the active component; then a ...

Article
Jan 1, 2024

Ivermectin Prescription Fill Rates Among U.S. Military Members During the Coronavirus Disease 2019 (COVID-19) Pandemic

This report describes ivermectin prescription fill rates among U.S. active component service members over time during the early phases of the COVID-19 pandemic. Ivermectin prescription fill rates increased among active component service members early in the COVID-19 pandemic when misinformation about the effectiveness of ivermectin for prevention and ...

Skip subpage navigation
Refine your search
Last Updated: May 07, 2024
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on X Follow us on YouTube Sign up on GovDelivery